MXPA02010231A - Inhibidores aminotransferasa dependientes de aminoacidos de cadena ramificada y su uso en el tratamiento de las enfermedades neurodegenerativas. - Google Patents
Inhibidores aminotransferasa dependientes de aminoacidos de cadena ramificada y su uso en el tratamiento de las enfermedades neurodegenerativas.Info
- Publication number
- MXPA02010231A MXPA02010231A MXPA02010231A MXPA02010231A MXPA02010231A MX PA02010231 A MXPA02010231 A MX PA02010231A MX PA02010231 A MXPA02010231 A MX PA02010231A MX PA02010231 A MXPA02010231 A MX PA02010231A MX PA02010231 A MXPA02010231 A MX PA02010231A
- Authority
- MX
- Mexico
- Prior art keywords
- treating
- disease
- neurodegenerative diseases
- treatment
- amino acid
- Prior art date
Links
- 230000004770 neurodegeneration Effects 0.000 title abstract 3
- 208000015122 neurodegenerative disease Diseases 0.000 title abstract 2
- 239000002380 aminotransferase inhibitor Substances 0.000 title 1
- 150000005693 branched-chain amino acids Chemical class 0.000 title 1
- 230000001419 dependent effect Effects 0.000 title 1
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- 206010002091 Anaesthesia Diseases 0.000 abstract 1
- 208000019901 Anxiety disease Diseases 0.000 abstract 1
- 101710105312 Branched-chain-amino-acid aminotransferase Proteins 0.000 abstract 1
- 101710097328 Branched-chain-amino-acid aminotransferase, cytosolic Proteins 0.000 abstract 1
- 101710194298 Branched-chain-amino-acid aminotransferase, mitochondrial Proteins 0.000 abstract 1
- 208000000094 Chronic Pain Diseases 0.000 abstract 1
- 206010010904 Convulsion Diseases 0.000 abstract 1
- 206010048843 Cytomegalovirus chorioretinitis Diseases 0.000 abstract 1
- 206010011878 Deafness Diseases 0.000 abstract 1
- 206010012689 Diabetic retinopathy Diseases 0.000 abstract 1
- 201000010374 Down Syndrome Diseases 0.000 abstract 1
- 208000010412 Glaucoma Diseases 0.000 abstract 1
- 208000023105 Huntington disease Diseases 0.000 abstract 1
- 208000013016 Hypoglycemia Diseases 0.000 abstract 1
- 208000019695 Migraine disease Diseases 0.000 abstract 1
- 208000002193 Pain Diseases 0.000 abstract 1
- 208000018737 Parkinson disease Diseases 0.000 abstract 1
- 101710158343 Probable branched-chain-amino-acid aminotransferase Proteins 0.000 abstract 1
- 208000028017 Psychotic disease Diseases 0.000 abstract 1
- 101710199693 Putative branched-chain-amino-acid aminotransferase Proteins 0.000 abstract 1
- 206010044688 Trisomy 21 Diseases 0.000 abstract 1
- 206010046543 Urinary incontinence Diseases 0.000 abstract 1
- 230000002411 adverse Effects 0.000 abstract 1
- 239000002647 aminoglycoside antibiotic agent Substances 0.000 abstract 1
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 abstract 1
- 230000037005 anaesthesia Effects 0.000 abstract 1
- 230000036506 anxiety Effects 0.000 abstract 1
- AZPBDRUPTRGILK-UHFFFAOYSA-N benzotriazol-1-ium-1-ylidenemethanediamine;4-methylbenzenesulfonate Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1.C1=CC=C2N(C(=N)N)N=NC2=C1 AZPBDRUPTRGILK-UHFFFAOYSA-N 0.000 abstract 1
- 230000019771 cognition Effects 0.000 abstract 1
- 230000036461 convulsion Effects 0.000 abstract 1
- 208000001763 cytomegalovirus retinitis Diseases 0.000 abstract 1
- 230000002708 enhancing effect Effects 0.000 abstract 1
- 239000003257 excitatory amino acid Substances 0.000 abstract 1
- 230000002461 excitatory amino acid Effects 0.000 abstract 1
- 230000010370 hearing loss Effects 0.000 abstract 1
- 231100000888 hearing loss Toxicity 0.000 abstract 1
- 208000016354 hearing loss disease Diseases 0.000 abstract 1
- 230000002218 hypoglycaemic effect Effects 0.000 abstract 1
- 230000001939 inductive effect Effects 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 208000014674 injury Diseases 0.000 abstract 1
- 208000028867 ischemia Diseases 0.000 abstract 1
- 206010027599 migraine Diseases 0.000 abstract 1
- 208000004296 neuralgia Diseases 0.000 abstract 1
- 208000021722 neuropathic pain Diseases 0.000 abstract 1
- 238000001356 surgical procedure Methods 0.000 abstract 1
- 230000008733 trauma Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/48—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups having nitrogen atoms of sulfonamide groups further bound to another hetero atom
- C07C311/49—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups having nitrogen atoms of sulfonamide groups further bound to another hetero atom to nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/14—The ring being saturated
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Pain & Pain Management (AREA)
- Ophthalmology & Optometry (AREA)
- Psychiatry (AREA)
- Obesity (AREA)
- Urology & Nephrology (AREA)
- Addiction (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Hospice & Palliative Care (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Psychology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US33363601P | 2001-11-27 | 2001-11-27 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MXPA02010231A true MXPA02010231A (es) | 2004-12-13 |
Family
ID=23303625
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MXPA02010231A MXPA02010231A (es) | 2001-11-27 | 2002-10-16 | Inhibidores aminotransferasa dependientes de aminoacidos de cadena ramificada y su uso en el tratamiento de las enfermedades neurodegenerativas. |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US6809119B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP1314723A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2003206273A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2002365311A1 (cg-RX-API-DMAC7.html) |
| BR (1) | BR0204863A (cg-RX-API-DMAC7.html) |
| CA (1) | CA2412466A1 (cg-RX-API-DMAC7.html) |
| MX (1) | MXPA02010231A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2003045902A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI252847B (en) * | 2001-07-10 | 2006-04-11 | Synta Pharmaceuticals Corp | Synthesis of taxol enhancers |
| MXPA02010231A (es) * | 2001-11-27 | 2004-12-13 | Warner Lambert Co | Inhibidores aminotransferasa dependientes de aminoacidos de cadena ramificada y su uso en el tratamiento de las enfermedades neurodegenerativas. |
| EP1877048A1 (en) * | 2005-04-15 | 2008-01-16 | Synta Pharmaceuticals Corporation | Combination cancer therapy with bis(thiohydrazide) amide compounds |
| AU2007288338B2 (en) | 2006-08-21 | 2012-05-03 | Synta Pharmaceuticals Corp. | Compounds for treating proliferative disorders |
| WO2008027445A2 (en) * | 2006-08-31 | 2008-03-06 | Synta Pharmaceuticals Corp. | Combination with bis(thiohydrazide amides) for treating cancer |
| US8093425B2 (en) | 2007-04-30 | 2012-01-10 | Synta Pharmaceuticals Corp. | Compounds for treating proliferative disorders |
| TWI490214B (zh) * | 2008-05-30 | 2015-07-01 | 艾德克 上野股份有限公司 | 苯或噻吩衍生物及該等作為ｖａｐ－１抑制劑之用途 |
| US20130331452A1 (en) | 2010-09-08 | 2013-12-12 | Wellstat Therapeutics Corporation | Benzoic acid compounds for reducing uric acid |
| BR112013018212B1 (pt) * | 2011-01-21 | 2021-12-14 | Sun Pharma Advanced Research Company Ltd | Inibidores de tirosino quinase contendo diarilacettleno hidrazida |
| EP2481801A1 (en) * | 2011-01-28 | 2012-08-01 | Deutsches Krebsforschungszentrum | Inhibitors of branched-chain-aminotransferase-1 (BCAT1) for the treatment of neoplasia |
| WO2014049471A1 (en) * | 2012-09-29 | 2014-04-03 | Mahesh Kandula | Compositions and methods for the treatment of ventricular arrhythmias and cardiovascular diseases |
| CN104610104B (zh) * | 2015-02-13 | 2016-06-01 | 佛山市赛维斯医药科技有限公司 | 一种含苯磺酰肼和硝基苯结构gpr119激动剂及其用途 |
| CN104592066B (zh) * | 2015-02-13 | 2016-04-06 | 佛山市赛维斯医药科技有限公司 | 一类苯磺酰肼化合物、制备方法及其用途 |
| CN104649938B (zh) * | 2015-02-13 | 2016-06-01 | 佛山市赛维斯医药科技有限公司 | 硝基苯磺酰肼类gpr119激动剂、制备方法及其用途 |
| CN104592065B (zh) * | 2015-02-13 | 2016-04-06 | 佛山市赛维斯医药科技有限公司 | 卤代苯磺酰肼类gpr119激动剂、制备方法及其用途 |
| CN104649944B (zh) * | 2015-02-13 | 2016-08-31 | 佛山市赛维斯医药科技有限公司 | 一类甲氧苯磺酰肼类gpr119激动剂、制备方法及其用途 |
| CN104610105B (zh) * | 2015-02-13 | 2016-04-06 | 佛山市赛维斯医药科技有限公司 | 烷基取代的苯磺酰肼类gpr119激动剂、制备方法及其用途 |
| CN104610103B (zh) * | 2015-02-13 | 2016-04-06 | 佛山市赛维斯医药科技有限公司 | 含苯磺酰肼和卤代苯结构gpr119激动剂、制备方法及其用途 |
| CN104649937B (zh) * | 2015-02-13 | 2016-04-13 | 佛山市赛维斯医药科技有限公司 | 苯磺酰肼类gpr119激动剂、制备方法及其用途 |
| CN104628612B (zh) * | 2015-02-13 | 2016-06-01 | 佛山市赛维斯医药科技有限公司 | 一类腈基苯磺酰肼类gpr119激动剂、制备方法及其用途 |
| GB201510019D0 (en) * | 2015-06-09 | 2015-07-22 | Cancer Therapeutics Crc Pty Ltd | Compounds |
| CN115715285B (zh) * | 2020-04-27 | 2025-09-09 | 奧土择破利悟 | 作为ubr盒结构域配体的化合物 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE69611437T2 (de) * | 1995-02-21 | 2001-08-23 | Nippon Suisan Kaisha, Ltd. | Gluteminsäurerezeptor agonisten |
| FR2792314B1 (fr) * | 1999-04-15 | 2001-06-01 | Adir | Nouveaux composes aminotriazoles, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| CN1626069A (zh) * | 1999-12-08 | 2005-06-15 | 沃尼尔·朗伯公司 | 支链氨基酸依赖性氨基转移酶的抑制剂及其在治疗糖尿病性视网膜病中的应用 |
| DE60111639T2 (de) * | 2000-09-19 | 2006-04-27 | Warner-Lambert Co. Llc | Hemmer der verzweigten aminosäure-abhängigen aminotransferase und deren verwendung in der behandlung von neurodegenerativen erkrankungen |
| MXPA03004821A (es) * | 2000-11-28 | 2004-03-26 | Guilford Pharm Inc | Compuestos de union de ciclofilina carbociclica bisubstutuida y su uso. |
| MXPA02010231A (es) * | 2001-11-27 | 2004-12-13 | Warner Lambert Co | Inhibidores aminotransferasa dependientes de aminoacidos de cadena ramificada y su uso en el tratamiento de las enfermedades neurodegenerativas. |
-
2002
- 2002-10-16 MX MXPA02010231A patent/MXPA02010231A/es unknown
- 2002-10-22 WO PCT/IB2002/004386 patent/WO2003045902A1/en not_active Ceased
- 2002-10-22 AU AU2002365311A patent/AU2002365311A1/en not_active Abandoned
- 2002-11-21 EP EP02258017A patent/EP1314723A1/en not_active Withdrawn
- 2002-11-25 CA CA002412466A patent/CA2412466A1/en not_active Abandoned
- 2002-11-26 BR BR0204863-9A patent/BR0204863A/pt not_active IP Right Cessation
- 2002-11-26 US US10/304,803 patent/US6809119B2/en not_active Expired - Fee Related
- 2002-11-27 JP JP2002344313A patent/JP2003206273A/ja active Pending
-
2004
- 2004-05-17 US US10/847,108 patent/US20050014841A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| JP2003206273A (ja) | 2003-07-22 |
| WO2003045902A1 (en) | 2003-06-05 |
| US6809119B2 (en) | 2004-10-26 |
| US20030149110A1 (en) | 2003-08-07 |
| AU2002365311A1 (en) | 2003-06-10 |
| CA2412466A1 (en) | 2003-05-27 |
| EP1314723A1 (en) | 2003-05-28 |
| US20050014841A1 (en) | 2005-01-20 |
| BR0204863A (pt) | 2004-06-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MXPA02010231A (es) | Inhibidores aminotransferasa dependientes de aminoacidos de cadena ramificada y su uso en el tratamiento de las enfermedades neurodegenerativas. | |
| AU4327101A (en) | Aminoadamantane derivatives as therapeutic agents | |
| IL168365A (en) | Use of a rasagaline with or without riluzole for preparing a medicament for treating amyotrophic lateral sclerosis | |
| ZA97991B (en) | Novel cyclic amino acids as pharmaceutical agents. | |
| ZA972200B (en) | Novel bridged cyclic amino acids as pharmaceutical agents. | |
| ZA972199B (en) | Novel bridged cyclic amino acids as pharmaceutical agents. | |
| MXPA03001277A (es) | Inhibidores de aminotransferasa dependientes de aminoacido de cadena ramificada y su uso en el tratamiento de enfermedades neurodegenerativas. | |
| ZA972496B (en) | Substituted 2,3-benzodiazepin-4-ones and the use thereof. | |
| NZ276892A (en) | Quinoxalinedione derivatives, preparation and use in pharmaceutical compositions thereof | |
| EP1983000A3 (en) | Method for the treatment of multiple sclerosis by inhibiting IL-17 activity | |
| WO2007087151A3 (en) | Combination of ache inhibitor and 5-ht6 antagonist for the treatment of cognitive dysfunction | |
| ATE359794T1 (de) | 3, 7 thiaprostansäurederivate als mittel zur verminderung des augeninnendruckes | |
| DE60234919D1 (de) | 3, 7 oder 3 und 7 thia- oder oxaprostansäure derivate als mittel zur senkung des augeninnendrucks | |
| WO2001068053A3 (en) | Methods and compositions for treating and preventing posterior segment ophthalmic disorders | |
| AU4673300A (en) | Amino heterocycles useful as pharmaceutical agents | |
| MXPA02010430A (es) | Inhibidores aminotransferasa dependientes de aminoacidos de cadena ramificada y su uso en el tratamiento de las enfermedades neurodegenerativas. | |
| HUT64841A (en) | Process and composition for treating eyes | |
| MXPA02011921A (es) | Inhibidores de dipeptidasa acida n-acetilada-alfa-enlazada para el tratamiento de trastornos retinianos y glaucona. | |
| WO2006002096A3 (en) | Low doses of l-citrulline for treating diseases | |
| WO2005046605A3 (en) | Compositions and methods of treating neurological diseases | |
| WO2008057599A3 (en) | Methods for the treatment of abeta related disorders and compositions therefor | |
| WO2023107630A3 (en) | Amino alcohol compounds and uses thereof | |
| WO2008027345A3 (en) | COMBINED γ-SECRETASE INHIBITOR AND PHENOTHIAZINE DERIVATIVE TREATMENT OF NEURODEGENERATIVE DISEASES | |
| BR0303209A (pt) | Composição farmacêutica para o tratamento de incontinência urinária feminina |